TOP > 外国特許検索 > SCREENING METHOD FOR ANTIDIABETIC AGENT USING NEWLY IDENTIFIED INSULIN SECRETION REGULATION FACTOR

SCREENING METHOD FOR ANTIDIABETIC AGENT USING NEWLY IDENTIFIED INSULIN SECRETION REGULATION FACTOR

外国特許コード F120006649
整理番号 S2010-1099
掲載日 2012年5月17日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP070067
国際公開番号 WO 2012029958
国際出願日 平成23年9月2日(2011.9.2)
国際公開日 平成24年3月8日(2012.3.8)
優先権データ
  • 特願2010-196952 (2010.9.2) JP
発明の名称 (英語) SCREENING METHOD FOR ANTIDIABETIC AGENT USING NEWLY IDENTIFIED INSULIN SECRETION REGULATION FACTOR
発明の概要(英語) The purpose of the present invention is to provide: a newly identified insulin secretion regulation factor that can control blood sugar within the normal range; and a screening method for an antidiabetic agent using said factor. The present invention provides: a composition that is (i) a protein containing an amino acid sequence represented by sequence number 2 or sequence number 4, or (ii) a protein containing an amino acid sequence represented by sequence number 2 or sequence number 4 wherein one or several amino acids have been deleted, substituted, or added, and negatively regulating insulin secretion; and a screening method for an antidiabetic agent using said protein or a nucleic acid that encodes same.
従来技術、競合技術の概要(英語) BACKGROUND ART
Diabetes mellitus, diseases associated with persistent hyperglycemia condition and, and a wide variety of environmental factors and is a result of genetic factors, that is said to be generated. The major regulator of blood glucose and insulin, hyperglycemia, insulin deficiency, or inhibits the action of the factors (for example, genetic predisposition, lack of exercise, obesity, stress and the like) in excess and grows are known to occur. Diabetes is, mainly, such as autoimmune diseases caused by deterioration of the pancreatic insulin secretory function by type 1 diabetes, insulin secretion due to high and sustained by pancreatic fatigue pancreatic insulin secreting function or insulin resistance which is caused by diabetes are classified into 2. In Japan, modern National Disease diabetes, a diabetic patient in 95% or more (pre-groups are included and 2,000 million more than predicted) is, referred to as non-insulin-dependent diabetes mellitus and, along with lifestyle changes, increase in the number of the patient in question. World level, estimated to be about 2 billion (non-patent document 1), the treatment of diabetes mellitus drugs in the market of the world, about 1 trillion circle to be the 2006 scale. This is, the second position are both approximately and artificial market in 1.
Is the treatment of diabetes, in mild, dieting, exercise regimens, and have been mainly such as improve and obesity, diabetes and proceed further oral administration of the drug (insulin secretagogues), in the case of further severe, administering an insulin formulation is being performed. Insulin secretagogues (or insulin secretagogues) include, in addition to glucose, amino acids (especially arginine), β receptor stimulants, α receptor blocking agent, known sulfonylurea agents and the like. Among these, sulfonylurea agents, pancreatic β cells were stimulated, promote endogenous insulin secretion, insulin secretion and the timing of and secretion amount, regardless of the blood glucose level, determined by the timing of administration of the drug and dosage. For this reason, as a side effect due to the effects of the drugs exhibits sustained hypoglycemia (non-patent document 2) is. In this way and conventionally used insulin formulation is insulin secretagogues, the problem was not recognized. Therefore, it is possible to more sophisticated glycemic control agent, that is, rather than simply blood glucose lowering agent, blood glucose within the normal range is desired that an agent capable of controlling has been. Therefore, useful as insulin secretagogues and insulin formulation for obtaining a substance having a simple screening method is required.
In addition, one amino acid is arginine L- 1, an operation of the many in vivo, for example, regulation of immune function, wound healing, hormone secretion, vascular tone, endothelial function, involved in insulin secretion (non-patent document 3). L - Arginine is, either directly or via a metabolite thereof, to mediate a number of physiological activity of a biologically active compound food products. In this connection, used as a substrate L- arginine arginine L- metabolizing enzymes are well known in the target agent (Arginine Interacting Factor: AIF). However, which also directly mediate the physiological actions of arginine L- little is known about not AIF. Up to now, the inventors of the present invention, developed its own L- arginine methyl ester (AME) is immobilized on the beads using the magnetic nanoparticles, they have succeeded in identification and purification of AIF (non-patent document 4). AME is, similar to arginine, arginine is promoting insulin secretion as agonists of, on the other hand, is AME, L-NAME(nitro -L- - arginine methyl ester) in the same manner, as antagonists of the arginine NOS suppressed (nitric oxide synthase). This AME - immobilized magnetic nano-beads, as PFK AIF (phosphofructokinase), RBL2 (2 RuvB-like), and RBL1 have been identified (RuvB-like 1) (non-patent document 4).
In addition, used in the screening methods of the present invention 'SEQ ID NO:2 protein comprising amino acid sequences represented by' is, the above-described non-patent document 4 magnetic nano-beads with immobilized AME isolated, a newly identified factor control insulin secretion. The amino acid sequence represented by SEQ ID NO:2 itself, to GenBank nm 198899as registered. However, until now, as described herein represented by SEQ ID NO:2 of an amino acid sequence, and a nucleotide sequence encoding the amino acid sequence is a nucleic acid, are involved in the promotion of insulin secretion is no report.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • Tokyo Institute of Technology
  • 発明者(英語)
  • IMAI, Takeshi
  • HANDA, Hiroshi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
詳しくお知りになりたい方は下記「問合せ先」まで直接お問合わせください

PAGE TOP

close
close
close
close
close
close